Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Abstract Background Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining c...

Full description

Bibliographic Details
Main Authors: Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero, Brian Gastman
Format: Article
Language:English
Published: BMJ Publishing Group 2018-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:http://link.springer.com/article/10.1186/s40425-018-0337-7

Internet

http://link.springer.com/article/10.1186/s40425-018-0337-7

Similar Items